Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Application

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term:

Results 1 - 5 of 5
EC Number Application Commentary Reference
Show all pathways known for 6.3.2.12Display the word mapDisplay the reaction diagram Show all sequences 6.3.2.12analysis a simple radioassay for dihydrofolate synthetase activity and its application to an inhibition study of new pteroate analogs 1013, 1017
Show all pathways known for 6.3.2.12Display the word mapDisplay the reaction diagram Show all sequences 6.3.2.12biotechnology production of active dihidrofolate synthase in milligram scale -, 650691
Show all pathways known for 6.3.2.12Display the word mapDisplay the reaction diagram Show all sequences 6.3.2.12drug development enzyme dihydrofolate synthase is a target for development of specific drugs against infections with the human pathogen Pneumocystis jirovecii that can cause pneumonia -, 744052
Show all pathways known for 6.3.2.12Display the word mapDisplay the reaction diagram Show all sequences 6.3.2.12medicine study on therapeutic efficacy of sulfadoxine-pyrimethamine at two locations in the Peruvian Amazon in order to correlate the presence of polymorphisms in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase to in vitro parasite susceptibility to sulfadoxine and pyrimethamine and to in vivo treatment outcomes. A single mutation present in the isolate obtained at the time of enrollment from either dihydrofolate reductase, 164L, or dihydropteroate synthase, 540E, predicts treatment failure as well as any other single gene alone or in combination. Patients carrying parasites with the dihydrofolate reductase 164L mutation are 3.6times as likely to be treatment failures while patients carrying parasites with the dihydropteroate synthase 540E mutation are 2.6times as likely to fail treatment. Patients with both dihydrofolate reductase 164L and dihydropteroate synthase 540E mutations are 4.1times as likely to be treatment failures compared to patients having both wild forms I164 and K540 706416
Show all pathways known for 6.3.2.12Display the word mapDisplay the reaction diagram Show all sequences 6.3.2.12medicine target for antimalarial therapy 705610
Results 1 - 5 of 5